Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
HR+/HER2− aromatase inhibitor-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the signaling transduction pathways, which everolimus resistance activates, will elucidate the mechanisms and offer treatment strategies of everolimus resistance.
To mimic the clinical setting, letrozole-resistant cells were used to generate an everolimus-resistant model (RAD-R). Reverse phase protein array (RPPA) was performed to reveal changes in the signaling transduction pathways, and expression levels of key proteins were analyzed. Inhibitors targeting the major signaling pathways, a CDK4/6 inhibitor palbociclib and a mTORC1/2 inhibitor (MLN0128), were evaluated to establish resistance mechanisms of RAD-R.
RPPA results from RAD-R indicated changes to significant regulatory pathways and upregulation of p-AKT expression level associating with everolimus resistance. MLN0128, that inhibits the AKT phosphorylation, effectively suppressed the proliferation of RAD-R cells while treatment with palbociclib had no effect.
Among the many signaling transduction pathways, which are altered post everolimus resistance, targeting dual mTORC1/2 is a possible option for patients who have recurrent disease from previous everolimus treatment.
KeywordsMTOR inhibitors MLN0128 Everolimus AI resistance
Letrozole-resistant cell line
Everolimus-resistant cell line
Reverse phase protein array
This work was supported by the Panda Charitable Foundation and the National Cancer Institute (P30CA033572).
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest.
- 10.Mayer IA et al (2014) Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202–1209CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Brufsky AM, Dickler, MN (2018) Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. OncologistGoogle Scholar
- 15.Finn RS et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35CrossRefPubMedGoogle Scholar
- 24.Cristofanilli M et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439CrossRefPubMedGoogle Scholar
- 28.Opyrcha M (2017) Palbociclib given after everolimus is associated with low response and clinical benefit rates in hr + metastatic breast cancer. in 2017 annual meeting of the american society of clinical oncology (ASCO). Chicago, Illinois: Oncology and Metastatic Breast CancerGoogle Scholar
- 35.Trials C (2018) MLN0128| Breast Cancer. https://clinicaltrials.gov/ct2/results?term=MLN0128&cond=Breast+Cancer